NS5A inhibitors in the treatment of hepatitis C

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Volume 63, Issue 1, Pages (July 2015)

Vincent Leroy, Jean-Pierre Zarski Journal of Hepatology

Volume 46, Issue 3, Pages (March 2007)

Inflammasomes in liver diseases

Volume 61, Issue 4, Pages (October 2014)

Volume 65, Issue 1, Pages S2-S21 (October 2016)

Volume 50, Issue 4, Pages (April 2009)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Volume 68, Issue 5, Pages (May 2018)

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Volume 51, Issue 6, Pages (December 2009)

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Volume 44, Issue 4, Pages (April 2006)

Volume 42, Issue 1, Pages (January 2005)

Immigration and viral hepatitis

Volume 66, Issue 1, Pages 1-4 (January 2017)

The evidence supports a viral aetiology for primary biliary cirrhosis

Ype P. de Jong, Charles M. Rice, Alexander Ploss Journal of Hepatology

Living donor liver transplantation: is the hype over?

David G. Bowen, Christopher M. Walker Journal of Hepatology

Volume 59, Issue 4, Pages (October 2013)

Volume 69, Issue 2, Pages (August 2018)

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

The place of downstaging for hepatocellular carcinoma

Jordan J. Feld, Graham R. Foster Journal of Hepatology

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

Hepatitis C core protein – The “core” of immune deception?

Vincent Leroy, Jean-Pierre Zarski Journal of Hepatology

Jean-Michel Pawlotsky Gastroenterology

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

From non-A, non-B hepatitis to hepatitis C virus cure

Volume 70, Issue 1, Pages (January 2019)

A dive into the complexity of type I interferon antiviral functions

Volume 44, Issue 2, Pages (February 2006)

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Daniel J. Felmlee, Thomas F. Baumert Journal of Hepatology

Ribavirin ante portas: Uptake transporters into hepatocytes dissected

Darius Moradpour, Arash Grakoui, Michael P. Manns

Autophagy in the liver Journal of Hepatology

Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore

Volume 62, Issue 1, Pages (January 2015)

EASL Clinical Practice Guidelines: Wilson’s disease

Volume 61, Issue 1, Pages S45-S57 (November 2014)

Volume 68, Issue 4, Pages (April 2018)

Economics of chronic hepatitis B and hepatitis C

HCV epidemiology in high-risk groups and the risk of reinfection

Volume 65, Issue 2, Pages (August 2016)

Volume 50, Issue 4, Pages (April 2009)

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Paul C. Adams, James C. Barton Journal of Hepatology

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6

Volume 56, Issue 6, Pages (June 2012)

Immigration and viral hepatitis

Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva

Global burden of alcoholic liver diseases

HCV targeting of patients with cirrhosis

Immunological techniques in viral hepatitis

Volume 63, Issue 1, Pages (July 2015)

Volume 51, Issue 2, Pages (August 2009)

Pathogenesis of cholestatic hepatitis C

Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing Roongruedee Chaiteerakij,

Chimeric mouse model of hepatitis B virus infection

Genetics of hepatocellular carcinoma: The next generation

Volume 60, Issue 5, Pages (May 2014)

Reversion of disease manifestations after HCV eradication

Presentation transcript:

NS5A inhibitors in the treatment of hepatitis C Jean-Michel Pawlotsky Journal of Hepatology Volume 59, Issue 2, Pages 375-382 (August 2013) DOI: 10.1016/j.jhep.2013.03.030 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Structural organization of HCV RNA and viral proteins. NS, non-structural; UTR, untranslated region. Journal of Hepatology 2013 59, 375-382DOI: (10.1016/j.jhep.2013.03.030) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Antiviral efficacy of ACH-3102 (second-generation NS5A inhibitor) compared with ACH-2928 and daclatasvir (first-generation NS5A inhibitors) on wild-type (parent) and mutated HCV replicons [69]. Journal of Hepatology 2013 59, 375-382DOI: (10.1016/j.jhep.2013.03.030) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions